Sienna Biopharmaceuticals, Inc. (SNNAQ)

Market Cap	23.00 -99.0%
Revenue (ttm)	n/a
Net Income	-47.95M
EPS	-1.80
Shares Out	22.78M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100
Open	0.0001
Previous Close	0.0001
Day's Range	0.0001 - 0.0001
52-Week Range	0.000001 - 0.0001
Beta	135.33
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About Sienna Biopharmaceuticals

Sienna Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs in various therapeutic areas. It develops therapies in immunology and inflammation that target select pathways in tissues, such as skin. The company’s lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical trial for the treatment of psoriasis and associated pruritus; and SNA-125, a topical dual Janus kinase 3 inhibitor that is in Phase I/II clinical trial...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 13
• Stock Exchange: OTCMKTS
• Ticker Symbol: SNNAQ

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 10, 2026

Data Sources Report a data error